Non Alcoholic Steatohepatitis (NASH) Market
Non Alcoholic Steatohepatitis (NASH) Market - Global Industry Assessment & Forecast
#
Pages:
169
Base Year:
2022
Jan - 2022
Format:
Report Code:
VMR-1253
Segments Covered
By
Drug Type Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cencicriviroc, Others
-
By
Sales Channel Hospital Pharmacy, Online Provider, Retail Pharmacy
-
By
Region North America, Latin America, Europe, Asia Pacific, Middle East & Africa
Snapshot
 Base Year:
|
2022 |
| Forecast
Years:
|
2023 - 2030 |
 Historical
Years:
|
2017 - 2021 |
 Revenue
2022: |
USD 2511.97 Million |
 Revenue 2030:
|
USD 108428.91 Million |
 Revenue CAGR
(2023 - 2030): |
60.10% |
Fastest Growing Region (2023 -
2030)
|
Asia Pacific |
Largest Region (2022):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
Non Alcoholic Steatohepatitis (NASH) Market Segment Analysis
- Non Alcoholic Steatohepatitis (NASH) Drug Type Outlook (Revenue, USD Million, 2018 - 2030)
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
- Non Alcoholic Steatohepatitis (NASH) Sales Channel Outlook (Revenue, USD Million, 2018 - 2030)
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
-
Regional Outlook (Revenue, USD Billion/Million, 2018 - 2030)
- North America
-
North America Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
-
North America Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- U.S.
- U.S. Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
- U.S. Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- U.S. Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Canada
- Canada Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
- Canada Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- Canada Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
-
Mexico
- Mexico Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
- Mexico Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- Mexico Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
-
North America Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Europe
-
Europe Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
-
Europe Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- U. K.
- U.K. Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
- U.K. Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- U.K. Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- France
- France Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
- France Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- France Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
-
Germany
- Germany Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
- Germany Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- Germany Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
-
Italy
- Italy Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
- Italy Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- Italy Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
-
Spain
- Spain Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
- Spain Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- Spain Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
-
Rest of Europe
- Rest of Europe Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
- Rest of Europe Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- Rest of Europe Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
-
Europe Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Asia Pacific
-
Asia Pacific Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
-
Asia Pacific Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- China
- China Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
- China Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- China Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Japan
- Japan Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
- Japan Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- Japan Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
-
Germany
- Germany Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
- Germany Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- Germany Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
-
India
- India Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
- India Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- India Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
-
South Korea
- South Korea Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
- South Korea Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- South Korea Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
-
South East Asia
- South East Asia Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
- South East Asia Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- South East Asia Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
-
Rest of Asia Pacific
- Rest of Asia Pacific Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
- Rest of Asia Pacific Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- Rest of Asia Pacific Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
-
Asia Pacific Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Latin America
-
Latin America Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
-
Latin America Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- Brazil
- Brazil Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
- Brazil Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- Brazil Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Argentina
- Argentina Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
- Argentina Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- Argentina Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
-
Rest of Latin America
- Rest of Latin America Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
- Rest of Latin America Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- Rest of Latin America Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
-
Latin America Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Middle East & Africa
-
Middle East & Africa Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
-
Middle East & Africa Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- GCC Countries
- GCC Countries Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
- GCC Countries Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- GCC Countries Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- South Africa
- South Africa Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
- South Africa Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- South Africa Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
-
Rest of Middle East & Africa
- Rest of Middle East & Africa Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
- Rest of Middle East & Africa Non Alcoholic Steatohepatitis (NASH) Market, by Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- Rest of Middle East & Africa Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
-
Middle East & Africa Non Alcoholic Steatohepatitis (NASH) Market, by Drug Type
- North America
Vantage Market
Research | 09-Feb-2022
FAQ
Frequently Asked Question
What is the global demand for Non Alcoholic Steatohepatitis (NASH) in terms of revenue?
-
The global Non Alcoholic Steatohepatitis (NASH) valued at USD 2511.97 Million in 2022 and is expected to reach USD 108428.91 Million in 2030 growing at a CAGR of 60.10%.
Which are the prominent players in the market?
-
The prominent players in the market are Genfit, Allergan plc (Tobira Therapeutics, Inc.), Bristol-Myers Squibb Company, Conatus Pharmaceuticals, Galectin Therapeutics, Inc..
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 60.10% between 2023 and 2030.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Non Alcoholic Steatohepatitis (NASH) include
- High Prevalence of Hypertension
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Non Alcoholic Steatohepatitis (NASH) in 2022.
